Develops treatments for kidney diseases and anemia management, focusing on dialysis care.
Rockwell Medical, Inc. is a biopharmaceutical company specializing in therapies and products aimed at addressing the needs of patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD) globally. Operating in the United States and internationally, the company focuses on developing innovative solutions for iron deficiency management and hemodialysis. Central to its offerings are Triferic Dialysate and Triferic AVNU, unique iron therapies designed to replenish iron and maintain hemoglobin levels in dialysis patients without increasing iron stores.
In addition to its pioneering iron therapies, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates, including CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, and other essential ancillary products. These concentrates are critical in dialysis treatment, facilitating the removal of toxins and the replenishment of vital nutrients essential for patient health.
Founded in 1996 and headquartered in Wixom, Michigan, Rockwell Medical continues to expand its product portfolio and research initiatives. Beyond dialysis care, the company is actively developing therapeutic candidates for acute heart failure management and home infusion therapy, underscoring its commitment to advancing patient care across diverse medical settings and enhancing outcomes for those with critical healthcare needs.